|
Sign In to gain access to subscriptions and/or personal tools.
|
Immune Modulator Studies in Primates: The Utility of Flow Cytometry and Immunohistochemistry in the Identification and Characterization of Immunotoxicity
P.B. Lappin
Sierra Biomedical, a Division of Charles River Laboratories, Sparks, Nevada 89431, plappin{at}sbi.criver.com
L.E. Black
Sierra Biomedical, a Division of Charles River Laboratories, Sparks, Nevada 89431
Exposure to natural environmental products, biopharmaceuticals, or investigational adjuvants has the potential to negatively impact the immune system, resulting in either up- or downregulation of immune function (immunomodulation). Many current protocols for primate toxicologic testing call for the evaluation of changes in immune cell number (peripheral blood or tissue), alterations in the weights of immune system organs (lymph nodes, spleen, thymus), and/or increases in the overall incidence of infections or neoplasms; these data are relied upon to suggest altered immune function. However, these are informative only when clear differences in frequency and/or severity of effects can be distinguished across control and dosed groups. In the absence of such distinct morphologic or clinical pathologic changes, the identification of potential immunomodulatory effects can present a much greater challenge. Additional evaluations may be needed to detect altered immune system integrity; these are based on in vivo assessments in primates of cellular or humoral responsiveness. Immunomodulatory effects can be characterized by in vitro or in vivo immune function tests; these tests require prestudy planning to integrate assessments into ongoing toxicology programs. These methods also involve specialized training and equipment, particularly if the intent is to evaluate parameters in a GLP laboratory setting. In primate toxicology, the added costs required to perform a complete functional analysis of the immune system can be substantial, but may be warranted depending on the clinical development plans. Two analytical methods that are easily incorporated into the standard toxicology profile in primates are flow cytometry and immunohistochemistry. Flow cytometry (FC) is used to assess changes in the relative distribution of immune cell marker expression, and where marker expression is known to fluctuate with the state of cell activation, can also provide information on functional attributes of immune cells. Immunohistochemistry (IHC) provides a means to evaluate similar characteristics of immune cells within tissue sections. Used together, FC and IHC can aid in the identification of changes in immune system that may not be apparent by traditional testing procedures (such as H&E staining), thus aiding in the characterization of immune system alterations. This presentation focused on the utility of flow cytometry and immunohistochemistry in a standard primate toxicology evaluation, with representative examples showing the benefits of these technologies in the diagnosis of potential immunomodulatory effects.
Key Words: Immunotoxicology • immunomodulators • biologics • primate safety assessment • immunophenotyping.
References
- Coles AJ, Wing M., Smith S., Coraddu F., Greer S., Taylor C., Weetman A., Hale G., Chatterjee VK, Waldmann H., Compston A. (1999). Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354: 1691—1695.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- International Conference on Harmonization (ICH) Harmonized Tripartite Guideline "S6" Note for Guidance on Preclinical Safety Evaluation of Biotechnology-derived Pharmaceuticals," (62 FR 61515, November 18, 1997; CPMP (Committee for Proprietary Medicinal Products )/ICH/302/95, September 1997).
- International Conference on Harmonization (ICH) Harmonized Tripartite Guideline "S7A" Note for Guidance on Safety Pharmacology Studies for Human Pharmaceuticals", (65 FR 48246, August, 2000; CPMP/ICH/ 539/00, November, 2000).
- Committee for Proprietary Medicinal Products (CPMP) " Note for Guidance on Repeated Dose Toxicity," (CPMP /SWP/1042/99, July 2000).
- Goldsby RA, Kindt TJ, Osborne BA (2000). Kuby Immunology, 4th ed, WH Freeman, New York, NY.
- Good Laboratory Practice Regulations, 21 CFR 58, Department of Health and Human Services, Food and Drug Administration, U.S. Government Printing Office, Washington, DC. Effective 1979.
- Green JD, Black LE (2000). Status of preclinical safety assessment for immunomodulatory biopharmaceuticals. Human Exp Toxicol 19: 208— 212.
- Hinton DM (2000). US FDA "Redbook II" immunotoxicity testing guidelines and research in immunotoxicity evaluations of food chemicals and new food proteins. Toxicol Pathol 28(3): 467—478.[Abstract/Free Full Text]
- House RV (2000). An overview of in vitro and ex vivo assays for preclinical evaluation of immunomodulation. Human Exper Toxicol 19: 246— 250.
- Ianelli, CJ Edson, CM, Thorley-Lawson, DA (1997 ). A ligand for human CD48 on epithelial cells. J Immunol 159(8): 3910—3920.[Abstract]
- Isaccs JD, Manna VK, Rapson N., Bulpitt KJ, Hazleman BL, Matteson EL, St Claire EW, Schnitzer TJ, Johnston JM (1996). CAMPATH-1H in rheumatoid arthritis—An intravenous dose ranging study. Br J Rheumatol 35(3): 132—140.
- The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group ( 1999). TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. Neurology 58: 457—465.
- Luster MI (1996). Immunotoxicology: Clinical consequences. Toxicol Ind Health 12(3—4): 533—535.[Free Full Text]
- Mohan N., Edwards E., Cupps TR, Oliverio PJ, Sandberg G., Crayton H., Richert JR, Siegel JN (2001). Demyelination occurring during anti-tumor necrosis factor: A therapy for inflammatory arthritides. Arthritis Rheum 44(12): 2862—2869.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Moreland LW, Pratt PW, Bucy RP, Jackson BS, Feldman JW, Koopman WJ (1994). Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term follow up of CD4+ T cell counts. Arthritis Rheum 37(6): 834—838.[Web of Science][Medline]
[Order article via Infotrieve]
- National Research Council ( 1992). Animal models for use in detecting immunotoxic potential and determining mechanisms of action in biological markers in immunotoxicology. In Biologic Markers in Immunotoxicology; Subcommittee on Biologic Markers, Committee on Biologic Markers, Board on Environmental Studies and Toxicology, National Research Council. National Academy Press, Washington, DC, pp 83—98.
- Remacade (Centocor, Malvern, PA) and Enbrel Package inserts (Immunex, Seattle, WA and Amgen, Thousand Oaks, CA). See Websites for Immunex and Centocor, respectively.
- Sicotte NL, Voskuhl RR (2001). Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57: 1885—1888.[Abstract/Free Full Text]
- US Food and Drug Administration (2001). Guidance for industry immunotoxicology evaluation of investigational new drugs. US Food and Drug Administration; Center for Drug Evaluation and Research.
Toxicologic Pathology, Vol. 31, No. 1 suppl,
111-118 (2003)
DOI: 10.1080/01926230390174986
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. S. Spoor, Z. A. Radi, and R. W. Dunstan
Characterization of Age- and Gender-related Changes in the Spleen and Thymus from Control Cynomolgus Macaques Used in Toxicity Studies
Toxicol Pathol,
July 1, 2008;
36(5):
695 - 704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
